What is the recommended guideline for switching a patient from dulaglutide 3 mg weekly to tirzepatide (Mounjaro)?

Switching from Dulaglutide 3 mg to Tirzepatide (Mounjaro)

When switching from dulaglutide 3 mg to tirzepatide, start tirzepatide at 2.5 mg once weekly and escalate by 2.5 mg every 4 weeks up to 15 mg, discontinuing dulaglutide at the time of tirzepatide initiation.

Switching Protocol

Based on FDA labeling and clinical trial evidence, the switch should follow this algorithm 1:

• Stop dulaglutide on your regularly scheduled day
• Start tirzepatide 2.5 mg subcutaneously once weekly on the same day (the 2.5 mg dose is for treatment initiation only, not glycemic control)
• Escalate after 4 weeks to 5 mg once weekly
• Continue escalating by 2.5 mg increments every 4 weeks as tolerated
• Target dose: 15 mg weekly (maximum approved dose for adults) 1

You can administer the first tirzepatide dose on the same day you would have taken your next dulaglutide dose, as there is no required washout period.

Expected Clinical Benefits

The SURPASS-SWITCH trial directly evaluated this switch and demonstrated 2:

• HbA1c reduction: Additional -0.77% reduction compared to escalating dulaglutide to 4.5 mg (tirzepatide achieved -1.44% vs dulaglutide -0.67% at 40 weeks)
• Weight loss: Additional -6.9 kg reduction compared to dulaglutide escalation (tirzepatide achieved -10.5 kg vs dulaglutide -3.6 kg)
• Benefits were consistent across all baseline characteristics including age, baseline HbA1c, diabetes duration, BMI, and ethnicity 3

Real-world data confirms these findings, with patients experiencing mean HbA1c reductions of 1.2% and weight loss of 3.6 kg at 6 months post-switch 4.

Critical Safety Considerations

Gastrointestinal tolerability is the primary concern when switching:

• Nausea and diarrhea are the most common adverse events 2, 5
• Discontinuation risk increases by 32% with tirzepatide compared to dulaglutide (RR 1.32 [1.20-1.45]) 5
• The slow dose escalation protocol (2.5 mg increments every 4 weeks) is specifically designed to minimize GI adverse events 1

Do not combine tirzepatide with GLP-1 receptor agonists - they should never be used together 6. Ensure dulaglutide is completely discontinued before starting tirzepatide.

Important Guideline Context

Recent 2025 BMJ guidelines provide critical context for this switch 6:

• If the patient has established cardiovascular or kidney disease: Tirzepatide should generally not replace dulaglutide unless an SGLT-2 inhibitor is also initiated or continued, as GLP-1 receptor agonists (like dulaglutide) have higher certainty evidence for cardiovascular and kidney protection
• If the primary goal is weight loss: Tirzepatide is preferred due to superior weight reduction (mean 8.63 kg vs baseline)
• Tirzepatide can be combined with SGLT-2 inhibitors but not with other GLP-1 receptor agonists 6

Administration Details

From FDA labeling 1:

• Inject subcutaneously in abdomen, thigh, or upper arm (rotate sites)
• Can be given any time of day, with or without meals
• If a dose is missed, administer within 4 days; if >4 days have passed, skip and resume regular schedule
• The day of weekly administration can be changed if at least 3 days (72 hours) pass between doses

Common Pitfalls to Avoid

1. Starting at too high a dose: Always start at 2.5 mg even though it's subtherapeutic - this minimizes GI side effects 1
2. Combining with dulaglutide: Never overlap these medications 6
3. Switching in high-risk cardiovascular patients without SGLT-2 inhibitor coverage: Ensure cardioprotective therapy is maintained 6
4. Escalating too quickly: Wait the full 4 weeks between dose increases 1
5. Inadequate patient counseling about GI effects: Proactive management of nausea/diarrhea improves persistence 5

Special Populations

• Oral contraceptives: May be less effective for 4 weeks after starting tirzepatide and 4 weeks after each dose increase - consider alternative contraception during these periods 1
• Pregnancy: Discontinue tirzepatide if pregnancy occurs 1
• Gastroparesis or severe GI disease: Use with extreme caution 1